Key facts
- Trotana Therapeutics’s last known valuation is $82.5M (Feb 2025).
- It has raised $70.5M; the latest was Later Stage VC ($52.5M) in Feb 2025.
- Notable investors include Andreessen Horowitz, ARCH Venture Partners, Lightstone Ventures, Medical Excellence Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Trotana Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Trotana Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Trotana Therapeutics
Operator of a biotech company intended to develop therapies and medicines. The company discovers and develops medicines targeting Ribonucleic acid (RNA)-binding proteins, enabling medical practitioners to get therapies for unmet needs for a variety of indications and diseases.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2019
- Employees
- 14
- Website
- trotana.com/
- Ownership
- Privately Held (backing)
Trotana Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Trotana Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Trotana Therapeutics in its N-PORT filings yet. We sweep new filings monthly.